Background: The ADHEAR™ system (MED-EL, Innsbruck, Austria) is a nonsurgical bone conduction device (BCD) to treat conductive hearing loss (CHL) and single-sided deafness. In contrast to the nonsurgical alternatives on headbands or spectacle frames, the audio processor of ADHEAR is placed retroauricularly on an adhesive adapter. The published evidence on the performance of this system is limited to studies with a trial period of 2–8 weeks. Objective: This study assesses audiological and subjective outcomes over a period of 12 months, on patients with congenital aural atresia (CAA) using the ADHEAR hearing system. Method: Fifteen children (mean age: 9.4 ± 4 years; range: 5–16 years) diagnosed with CAA (7 uni/8 bilateral) were included in this prospective, observational, repeated-measures study. Each subject used ADHEAR for 1 year, and the performance was evaluated after 1, 6, and 12 months. Free-field audiometry and speech discrimination tests were performed, and hearing-, general health- and device-specific questionnaires were used. Results: The unaided sound field threshold improved from an average PTA4 of 63.6 ± 3.4 dB HL to an aided average PTA4 of 29.3 ± 3.0 dB HL after 1 month of device use. The word recognition score (WRS) improved from an average of 27.9 ± 15.9% unaided to an aided average WRS of 91.3 ± 4.4% (p = 0.0003) after 1 month, 92.0 ± 4.1% (p = 0.0002) after 6 months, and 92.7 ± 5.3% (p < 0.0001) after 12 months using the ADHEAR system compared to the unaided condition for all 3 time points. The improvements in the speech in noise at 1, 6, and 12 months were as well consistent over time. The average improvement at the signal to noise ratio (SNR) of +5 dB was 58% and 53% at the SNR of +0 dB. No complications were reported, and all patients continued to use the ADHEAR after the study end. The questionnaire results revealed high user satisfaction and an average wearing time of 12 h per day. Conclusion: This 12-month trial of the nonsurgical adhesive BCD in CAA patients showed sufficient and reliable audiological and subjective outcomes, long wearing time, and high acceptance. The ADHEAR can be considered a suitable option to treat children with CAA for the given indication, without the drawbacks of nonsurgical devices that use pressure for retention of the audio processor or the costs and possible complications involved with a surgical alternative.

1.
Badran
K
,
Arya
AK
,
Bunstone
D
,
Mackinnon
N
.
Long-term complications of bone-anchored hearing aids: a 14-year experience
.
J Laryngol Otol
.
2009
;
123
(
2
):
170
6
. .
2.
Billinger-Finke
M
,
Bräcker
T
,
Weber
A
,
Amann
E
,
Anderson
I
,
Batsoulis
C
.
Development and validation of the audio processor satisfaction questionnaire (APSQ) for hearing implant users
.
Int J Audiol
.
2020 May
;
59
(
5
):
392
7
. .
3.
Dahm
V
,
Auinger
AB
,
Liepins
R
,
Baumgartner
WD
,
Riss
D
,
Arnoldner
C
.
A randomized cross-over trial comparing a pressure-free, adhesive to a conventional bone conduction hearing device
.
Otol Neurotol
.
2019 Jun
;
40
(
5
):
571
7
. .
4.
Dahm
V
,
Baumgartner
WD
,
Liepins
R
,
Arnoldner
C
,
Riss
D
.
First results with a new, pressure-free, adhesive bone conduction hearing aid
.
Otol Neurotol
.
2018 Jul
;
39
(
6
):
748
54
. .
5.
Favoreel
A
,
Heuninck
E
,
Mansbach
AL
.
Audiological benefit and subjective satisfaction of children with the ADHEAR audio processor and adhesive adapter
.
Int J Pediatr Otorhinolaryngol
.
2020
;
129
:
109729
. .
6.
Gawliczek
T
,
Munzinger
F
,
Anschuetz
L
,
Caversaccio
M
,
Kompis
M
,
Wimmer
W
.
Unilateral and bilateral audiological benefit with an adhesively attached, noninvasive bone conduction hearing system
.
Otol Neurotol
.
2018 Sep
;
39
(
8
):
1025
30
. .
7.
Neumann
K
,
Thomas
JP
,
Voelter
C
,
Dazert
S
.
A new adhesive bone conduction hearing system effectively treats conductive hearing loss in children
.
Int J Pediatr Otorhinolaryngol
.
2019
;
122
:
117
25
. .
8.
O’Niel
MB
,
Runge
CL
,
Friedland
DR
,
Kerschner
JE
.
Patient outcomes in magnet-based implantable auditory assist devices
.
JAMA Otolaryngol Head Neck Surg
.
2014
;
140
:
513
20
.
9.
Osborne
MS
,
Child-Hymas
A
,
Gill
J
,
Lloyd
MS
,
McDermott
AL
.
First pediatric experience with a novel, adhesive adapter retained, bone conduction hearing aid system
.
Otol Neurotol
.
2019 Oct
;
40
(
9
):
1199
207
. .
10.
Ravens-Sieberer
U
,
Herdman
M
,
Devine
J
,
Otto
C
,
Bullinger
M
,
Rose
M
,
The European KIDSCREEN approach to measure quality of life and well-being in children: development, current application, and future advances
.
Qual Life Res
.
2014
;
23
(
3
):
791
803
. .
11.
Shapiro
S
,
Ramadan
J
,
Cassis
A
.
BAHA skin complications in the pediatric population: systematic review with meta-analysis
.
Otol Neurotol
.
2018 Aug
;
39
(
7
):
865
73
. .
12.
Skarzynski
PH
,
Ratuszniak
A
,
Osinska
K
,
Koziel
M
,
Krol
B
,
Cywka
KB
,
A comparative study of a novel adhesive bone conduction device and conventional treatment options for conductive hearing loss
.
Otol Neurotol
.
2019 Aug
;
40
(
7
):
858
64
. .
13.
Zarowski
AJ
,
Verstraeten
N
,
Somers
T
,
Riff
D
,
Offeciers
EF
.
Headbands, testbands and softbands in preoperative testing and application of bone-anchored devices in adults and children
.
Adv Otorhinolaryngol
.
2011
;
71
:
124
31
. .
14.
Zernotti
ME
,
Curet
CA
,
Cortasa
S
,
Chiaraviglio
M
,
Di Gregorio
MF
.
Congenital aural atresia prevalence in the Argentinian population
.
Acta Otorrinolaringol Esp
.
2019 Jan–Feb
;
70
(
1
):
32
5
. .
15.
Zernotti
ME
,
Sarasty
AB
.
Active bone conduction prosthesis: bonebridge (TM)
.
Int Arch Otorhinolaryngol
.
2015
;
19
(
4
):
343
8
. .
16.
Zhong
Y
,
Xu
T
,
Dong
R
,
Lyu
J
,
Liu
B
,
Chen
X
.
The analysis of reliability and validity of the IT-MAIS, MAIS and MUSS
.
Int J Pediatr Otorhinolaryngol
.
2017 May
;
96
:
106
10
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.